[Changes in elastase and collagenase serum levels in patients with sclerosing connective tissue diseases treated with uropancreozymin].
BACKGROUND
The objective of this work is to clarify the mechanism of the therapeutic effect of uropancreozymin upon the sclerosal process.


RESULTS
The sick suffering from sclerosed connective tissue formation underwent uropancreozymin treatment. Their elastase and collagenase blood serum level was contemporaneously determined. One day after the administration of uropancreozymin the elastase level rose by 144.6%, after the third day by 187.4%, after the seventh day by 150.2%. The collagenase activity was elevated after the first day of treatment to 234.7%, after the third day by 187.4%, after the seventh day by 150.2%. The collagenase activity was elevated after the first day of treatment to 144.6%, after the third day to 132.7%, and after the seventh day to 150.8%.


CONCLUSIONS
The therapeutic effect of uropancreozymin is explained as the faculty to wash out the pancreatic enzymes in active form, mainly elastase et collagenase, into the blood circulation. So it differs from pancreozymin which does not elevate the pancreatic enzyme level in blood in these diseases and which contains more hormonal factors. For this reason uropancreozymin is therapeutic and pancreozymin diagnostic. Pancreozymin was later mistakenly characterized as cholecystokinin (4.9) but this error has been already repaired (17).
Hodác
V
V
Kozní oddĕlení, Nemocnice Ceské Budĕjovice.
Vyhnánek
J
J
Svatos
A
A
D002766:Cholecystokinin / Q000627:therapeutic use*; D017364:Collagenases / Q000097:blood*; D003240:Connective Tissue Diseases / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D010196:Pancreatic Elastase / Q000097:blood*; D012598:Sclerosis
D002766:Cholecystokinin; D010196:Pancreatic Elastase; D017364:Collagenases
Zmĕny koncentrace elastázy a kolagenázy v krevním séru nemocyných s chorobami s tvorbou sklerotické vazivové tkánĕ bĕhem lécby uropankreozyminem.